CervoMed Inc.
CRVO evidence brief
What we can confirm
- BioSniper Score:
- 8.1 / 10
- Market Cap:
- $38.9M
What it means
What to watch
Prepared research question
What matters most for CRVO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRVO
CervoMed Inc. (CRVO) is a clinical-stage biotechnology company developing neflamapimod, an oral small-molecule drug candidate for dementia with Lewy bodies and other age-related brain disorders [sec · filed 2026-07-06].
Key risk: No approved products or revenue
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$38.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
CervoMed Inc. (CRVO) is a clinical-stage biotechnology company developing neflamapimod, an oral small-molecule drug candidate for dementia with Lewy bodies and other age-related brain disorders [sec · filed 2026-07-06].
- Lead drug candidate neflamapimod is being studied in Phase 2b RewinD-LB trial for dementia with Lewy bodies and has shown increased basal forebrain volume and functional connectivity [sec · filed 2026-04-22].
- Completed enrollment in a Phase 2a study of neflamapimod for nfvPPA, a type of frontotemporal dementia, with first biomarker data expected in early Q4 2026 and first clinical data in Q1 2027 [news · published 2026-07-09].
- Neflamapimod was selected for inclusion in the UK-funded EXPERTS-ALS platform for rapid testing of potential treatments for amyotrophic lateral sclerosis [news · published 2026-02-18].
- As of 2026-06-30, the company reported cash & equivalents of $22.5M, zero revenue, a net loss of -$6.6M, and shareholders' equity of $23.0M [sec].
- A private placement expected to raise approximately $10.5 million in gross proceeds (with potential additional $21.7 million from warrant exercises) closed on or about June 11, 2026 [sec · filed 2026-06-10].
What works
- Neflamapimod has generated positive biomarker data in the Phase 2b RewinD-LB trial, demonstrating increased basal forebrain volume and functional connectivity in DLB patients [sec · filed 2026-04-22].
- The drug candidate has been selected for the UK-funded EXPERTS-ALS platform, providing a non-dilutive pathway to test efficacy in ALS [news · published 2026-02-18].
- CervoMed has completed enrollment in a Phase 2a study for nfvPPA, expanding its pipeline beyond DLB into another neurodegenerative indication [news · published 2026-07-09].
- The company has a cash position of $22.5M as of 2026-06-30, supplemented by a recent $10.5M private placement, providing runway for ongoing trials [sec].
What to weigh
- CervoMed has no approved products and reported zero revenue as of 2026-06-30, with a net loss of -$6.6M for the period [sec].
- The company's forward-looking statements acknowledge risks around its ability to obtain additional financing and to enter into a partnership to advance neflamapimod into Phase 3 for DLB [sec · filed 2026-07-06].
- The Phase 2b RewinD-LB data presented so far are biomarker results, not clinical efficacy outcomes, and the company has not yet reported topline Phase 2 results for DLB [sec · filed 2026-04-22].
- The company's pipeline is heavily dependent on a single drug candidate, neflamapimod, across multiple indications, concentrating risk [news · published 2026-07-09].
From the filings
Quoted directly from source documents.
Neflamapimod increased basal forebrain volume and functional connectivity in DLB patients in Phase 2b trial
“neflamapimod increased basal forebrain volume and functional connectivity in patients with dementia with Lewy bodies”
SEC filings · April 22, 2026
CervoMed completed enrollment in Phase 2a study for nfvPPA
“CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has completed enrollment in the Phase 2a study”
News · July 9, 2026
Neflamapimod selected for EXPERTS-ALS platform
“its lead drug candidate, neflamapimod, has been selected for inclusion in EXPERTS-ALS, a platform funded by the by the United Kingdom National Institute for Health and Care Research and leading motor neuron disease charities”
News · February 18, 2026
Catalyst timeline
- 2027-03-31 · Phase 2 Readout: neflamapimod — Topline results from the Phase 2 study of neflamapimod in dementia with Lewy bodies are expected, which will inform the path to Phase 3.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — CervoMed reported zero revenue and a net loss of -$6.6M as of 2026-06-30, with no approved products [sec].
- Single drug candidate dependency — All pipeline programs rely on neflamapimod, concentrating clinical and regulatory risk [news · published 2026-07-09].
- Phase 3 partnership uncertainty — The company acknowledges risk in its ability to enter into a partnership to advance neflamapimod into Phase 3 for DLB [sec · filed 2026-07-06].
- Financing risk — Forward-looking statements note risk around ability to obtain additional financing on acceptable terms or at all [sec · filed 2026-07-06].
What to watch
- First biomarker data from the Phase 2a nfvPPA study expected in early Q4 2026 [news · published 2026-07-09].
- First clinical data from the Phase 2a nfvPPA study expected in Q1 2027 [news · published 2026-07-09].
- Phase 2 topline readout for neflamapimod in DLB expected by 2027-03-31 [catalyst].
- Potential partnership or financing developments to support Phase 3 for DLB [sec · filed 2026-07-06].
Sources: Catalysts · News · SEC filings · Generated October 14, 2026 · How we verify sources →
Run CervoMed Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CervoMed Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.13
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
36
Total value held
$7.0M
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 739,892 | $2.9M |
| vanguard capital management llc | 316,202 | $1.2M |
| millennium management llc | 208,908 | $823K |
| geode capital management, llc | 74,371 | $293K |
| renaissance technologies llc | 63,904 | $252K |
| blackrock, inc. | 51,660 | $204K |
| xtx topco ltd | 38,487 | $152K |
| citizens financial group inc/ri | 37,477 | $148K |
| vanguard fiduciary trust co | 36,151 | $142K |
| northern trust corp | 30,044 | $118K |
Showing top 10 of 36 institutional holders of CervoMed Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.4%
- Days to cover
- 7.5
- Shares short
- 281,907
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRVO short interestGovernance
Frequently asked questions
What is the AI investment thesis for CervoMed Inc.?
CervoMed Inc. (CRVO) is a clinical-stage biotechnology company developing neflamapimod, an oral small-molecule drug candidate for dementia with Lewy bodies and other age-related brain disorders [sec · filed 2026-07-06].
Who is the CEO of CervoMed Inc.?
Dr. John J. Alam M.D. is the chief executive officer of CervoMed Inc. (CRVO).
Where is CervoMed Inc. headquartered?
CervoMed Inc. (CRVO) is headquartered in Boston, MA, United States.
What therapeutic areas does CervoMed Inc. focus on?
CervoMed Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.